benserazide (PB-04) / Phoenicia Biosciences - LARVOL DELTA

Initial Results in a Phase 1b Trial of PB-04 in Sickle Cell Disease Demonstrate Fetal Hemoglobin Induction, Additive Activity with Hydroxyurea, and Improved Red Blood Cell Sickling Parameters (ASH 2023) - P1/2 | "Correlation of HbF quantity/cell with RBC survival and sickling dynamics is being explored. These early results with not-yet-optimized doses of PB-04 suggest additive activity with HU, producing significant HbF and F-cell levels, and support further PK-optimized studies in patients with SCD."

P1 data • Beta-Thalassemia • Cardiovascular • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • VCAM1

Should COMT inhibition always be used with levodopa/dopa-decarboxylase inhibitor (DDI; carbidopa/benserazide)? Yes (CONy 2020) - No abstract available.